UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2019
Commission File Number 001-38370
CollPlant Holdings Ltd.
(Exact name of registrant as specified in its charter)
3 Sapir Street, Weizmann Science Park
Ness Ziona 74140, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
The first and fourth paragraphs and “Forward Looking Statements” of the press release attached to this Form 6-K are hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163) and Form F-3 (File No. 333-229486), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Attached hereto as Exhibit 99.1 and incorporated by reference herein is a press release issued by the Registrant entitled “Study Published in Wounds Journal Shows Remarkable Wound Closure Performance with CollPlant’s VergenixFG in the Treatment of Chronic Wounds with a 94% Median Wound Area Reduction within 4-weeks”.
Exhibit | ||
99.1 | Press Release, dated March 11, 2019 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
COLLPLANT HOLDINGS LTD. | ||
Date: March 11, 2019 | By: | /s/ Eran Rotem |
Name: Eran Rotem | ||
Title: Deputy CEO and Chief Financial Officer |
2